Company intelligence / Profile preview

Gubra

Hørsholm, Denmarkgubra.dk ↗

Ownership: Public · GUBRA
Employees: ~200
Development stage: Phase 1

Overview

Gubra has a robust R&D pipeline with both internal and partnered programs. Four projects are in clinical development, including two in Phase I. The company’s lead asset is an amylin analog for weight management that has been partnered with AbbVie in a deal worth up to $2.2 billion. Other programs target metabolic and fibrotic indications using advanced peptide modalities.

Therapeutic areas: OtherEndocrinologyImmunologyMetabolic Disorders
Modalities: PeptidesPeptide-drug conjugateSmall molecule (as part of preclinical profiling services)
Industry: Biotech

Drug pipeline

1 asset

GUB-UCN2

Partnerships

AbbVie ($2.2B+ deal for amylin analog "GUBamy")Boehringer IngelheimBayerSilence TherapeuticsHemab Therapeutics

Financials

Market cap: $377.7M
Total revenue: $82.5M
Enterprise value: $162.4M

Beyond the preview

Go deeper on Gubra.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gubra.

Explore the full profile